One pharmacist. One knowledge-based company. One year. $2.7 million savings.

April 20, 2018

One pharmacist evaluating specialty drug claims using integrated medical and pharmacy claims and PA data can identify enough savings opportunities to achieve a 9:1 ROI 

In this study, one managed care pharmacist armed with advance analytics worked through integrated medical and pharmacy benefit claims records. By collaborating with the Blue Plan insurer case management team, the pharmacist was able to optimize drug therapy. This resulted in substantial drug savings.

After reviewing approximately 1,500 member files, 365 were identified as having an actionable opportunity. The pharmacist reviewed the drug therapy regimens of selected high-drug-cost identified members. The regimens were evaluated to ensure appropriate use, identify suspicious utilization, and discover savings opportunities. Advanced analytics combed through millions of member files to zero in on 1,500 members to assess. Of the 365, 20 resulted in validated savings. 

Savings opportunities were classified as: 

  • Changes in drug dosing units 
  • Therapy changes
  • PA approval process changes 
  • FWA recovery and future claims avoidance

While 20 may sound like a small number, the high-value opportunities and PA process changes added up quickly, to a total of $2.7 million. 

For example, a change to the detailing process to ensure correct number of fills in hepatitis C claims affected 28 members and added up to $1 million in savings. Package size optimization for seven members using secukinumab Prime calls another win for carve-in pharmacy benefits; it’s just better than carve-outsaved $327,000.  

After subtracting salary and administrative costs of $300,000, final savings totaled $2.4 million, giving a return on investment of 9:1. All savings were validated by claims or by the health plan. 

Related news

Perspectives

July 25, 2024

Quarterly Drug Pipeline: July 2024

Clinical insights and competitive intelligence on anticipated drugs in development

Stories

July 22, 2024

Introducing the latest issue of our medical and pharmacy benefit management report

The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care

Perspectives

July 22, 2024

Oncology Insights: 2024 ASCO Annual Meeting key findings

Findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting will likely lead to clinical practice changes and U.S. Food and Drug Administration (FDA) drug approvals or expansions